PMID- 23886139
OWN - NLM
STAT- MEDLINE
DCOM- 20140219
LR  - 20190606
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Linking)
VI  - 14
IP  - 6
DP  - 2013
TI  - KAI1/CD82 and MRP1/CD9 serve as markers of infiltration, metastasis, and 
      prognosis in laryngeal squamous cell carcinomas.
PG  - 3521-6
AB  - OBJECTIVE: The current study explored the expression of KAI1/CD82 and MRP1/CD9 
      and its significance in laryngeal squamous cell carcinoma (LSCC). METHODS: The 
      expression levels of KAI1/CD82 and MRP1/CD9 in 100 LSCC tissue specimens, as well 
      as in 30 para-LSCC non-carcinomatous tissue specimens randomly taken from the 
      patients, were assessed using the quantitative polymerase chain reaction (Q-PCR) 
      and immunohistochemistry and correlations with pathological parameters of LSCC 
      and their influence on survival function were analyzed. RESULTS: KAI1/CD82 and 
      MRP1/CD9 showed basically consistent changes in both mRNA and protein expression. 
      Their expression in the 30 LSCC specimens was significantly lower compared with 
      that in the corresponding non-carcinous tissues (P < 0.01 or 0.05), notably 
      correlating with TNM stage, differentiation degree, clinical stage, and lymphatic 
      metastasis (P < 0.01 or 0.05), but not gender, age, and LSCC growth sites (P > 
      0.05). The median survival of patients with positive KAI1/CD82 and MRP1/CD9 
      protein expression was longer than that of patients with negative protein 
      expression (P < 0.01 or 0.05). KAI1/CD82 protein expression negatively correlated 
      with MRP1/CD9 protein expression in LSCC (chi(2) = 31.25, P < 0.01). CONCLUSION: 
      KAI1/CD82 and MRP1/CD9 may jointly participate in the development of LSCC. They 
      may serve as the markers for judging the infiltration, metastasis, and prognosis 
      of LSCC.
FAU - Zhang, Bing-Hui
AU  - Zhang BH
AD  - Department of Otolaryngology/Head and Neck Surgery, the Second Affiliated 
      Hospital of Harbin Medical University, Harbin, China.
FAU - Liu, Wei
AU  - Liu W
FAU - Li, Liang
AU  - Li L
FAU - Lu, Jian-Guang
AU  - Lu JG
FAU - Sun, Ya-Nan
AU  - Sun YN
FAU - Jin, De-Jun
AU  - Jin DJ
FAU - Xu, Xiu-Yu
AU  - Xu XY
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD82 protein, human)
RN  - 0 (CD9 protein, human)
RN  - 0 (Kangai-1 Protein)
RN  - 0 (Multidrug Resistance-Associated Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (Tetraspanin 29)
RN  - Y49M64GZ4Q (multidrug resistance-associated protein 1)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/genetics/*metabolism
MH  - Carcinoma, Squamous Cell/metabolism/*mortality/secondary
MH  - Case-Control Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Kangai-1 Protein/genetics/*metabolism
MH  - Laryngeal Neoplasms/metabolism/*mortality/pathology
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Multidrug Resistance-Associated Proteins/genetics/*metabolism
MH  - Neoplasm Invasiveness
MH  - Neoplasm Recurrence, Local/metabolism/*mortality/pathology
MH  - Neoplasm Staging
MH  - Prognosis
MH  - RNA, Messenger/genetics
MH  - Real-Time Polymerase Chain Reaction
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Survival Rate
MH  - Tetraspanin 29/genetics/*metabolism
EDAT- 2013/07/28 06:00
MHDA- 2014/02/20 06:00
CRDT- 2013/07/27 06:00
PHST- 2013/07/27 06:00 [entrez]
PHST- 2013/07/28 06:00 [pubmed]
PHST- 2014/02/20 06:00 [medline]
AID - 10.7314/apjcp.2013.14.6.3521 [doi]
PST - ppublish
SO  - Asian Pac J Cancer Prev. 2013;14(6):3521-6. doi: 10.7314/apjcp.2013.14.6.3521.